Harvard Bioscience (HBIO)
(Delayed Data from NSDQ)
$2.66 USD
-0.04 (-1.48%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $2.65 -0.01 (-0.38%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum A VGM
Balance Sheet
Fiscal Year End for Harvard Bioscience, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 4 | 5 | 8 | 8 | 8 |
Receivables | 16 | 17 | 22 | 18 | 21 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 25 | 26 | 28 | 22 | 22 |
Other Current Assets | 4 | 3 | 4 | 3 | 2 |
Total Current Assets | 49 | 51 | 62 | 52 | 54 |
Net Property & Equipment | 4 | 3 | 3 | 4 | 5 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 73 | 77 | 85 | 92 | 96 |
Deposits & Other Assets | 6 | 8 | 5 | 1 | 2 |
Total Assets | 137 | 145 | 162 | 156 | 165 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 6 | 5 | 6 | 5 |
Current Portion Long-Term Debt | 6 | 4 | 3 | 2 | 7 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 14 | 11 | 15 | 11 | 10 |
Total Current Liabilities | 27 | 23 | 25 | 21 | 25 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 2 | 2 | 2 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 31 | 43 | 45 | 46 | 47 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 0 | 3 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 64 | 73 | 79 | 80 | 83 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 232 | 229 | 226 | 232 | 229 |
Retained Earnings | -146 | -142 | -133 | -132 | -125 |
Other Equity | -14 | -15 | -10 | -13 | -13 |
Treasury Stock | 0 | 0 | 0 | 11 | 11 |
Total Shareholder's Equity | 73 | 72 | 83 | 77 | 82 |
Total Liabilities & Shareholder's Equity | 137 | 145 | 162 | 156 | 165 |
Total Common Equity | 73 | 72 | 83 | 77 | 82 |
Shares Outstanding | 42.60 | 41.60 | 40.80 | 38.90 | 38.00 |
Book Value Per Share | 1.72 | 1.74 | 2.04 | 1.97 | 2.15 |
Fiscal Year End for Harvard Bioscience, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 4 | 4 | 4 | 5 | 4 |
Receivables | 12 | 15 | 16 | 15 | 17 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 25 | 24 | 25 | 26 | 26 |
Other Current Assets | 5 | 4 | 4 | 4 | 5 |
Total Current Assets | 46 | 48 | 49 | 50 | 53 |
Net Property & Equipment | 5 | 4 | 4 | 3 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 70 | 71 | 73 | 73 | 75 |
Deposits & Other Assets | 3 | 5 | 6 | 8 | 6 |
Total Assets | 129 | 133 | 137 | 140 | 143 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 6 | 6 | 6 | 5 |
Current Portion Long-Term Debt | 4 | 4 | 6 | 3 | 3 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 13 | 15 | 14 | 12 | 13 |
Total Current Liabilities | 23 | 26 | 27 | 24 | 23 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 1 | 1 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 32 | 32 | 31 | 35 | 38 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 1 | 1 | 1 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 62 | 64 | 64 | 65 | 68 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 235 | 233 | 232 | 233 | 232 |
Retained Earnings | -153 | -150 | -146 | -144 | -143 |
Other Equity | -15 | -15 | -14 | -15 | -14 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 67 | 69 | 73 | 74 | 75 |
Total Liabilities & Shareholder's Equity | 129 | 133 | 137 | 140 | 143 |
Total Common Equity | 67 | 69 | 73 | 74 | 75 |
Shares Outstanding | 43.40 | 43.40 | 42.60 | 42.60 | 42.10 |
Book Value Per Share | 1.55 | 1.59 | 1.72 | 1.74 | 1.79 |